A September 4 commentary in Pharmacy Times argues that state boards of pharmacy need to take a more active role in stopping illegal retatrutide from reaching patients through pharmacies, medical spas, online sellers, and other channels (Pharmacy Times). The article is an opinion piece by John Hertig, PharmD, MS, CPPS, FASHP, FFIP, an international patient-safety expert and chair of the Collaborative for Evidence-Based Medicines. It is not a new clinical study or a finding about Lilly’s pharmaceutical-grade investigational product.
Retatrutide remains an investigational medicine. It has not been approved by the FDA, Health Canada, or any other regulator, and products advertised as “compounded retatrutide” or “research use only” are not made legitimate by those labels. The U.S. Food and Drug Administration warns about the risks of unapproved GLP-1 products, including uncertainty about identity, quality, concentration, sterility, and manufacturing controls (FDA).
Why pharmacy boards matter
The Pharmacy Times commentary distinguishes federal enforcement from professional and pharmacy oversight. The FDA can pursue companies that market unapproved drugs, but state pharmacy boards license pharmacists and pharmacies, including non-resident pharmacies that ship across state lines. Hertig argues that boards should investigate complaints, inspect sourcing and advertising records, review disciplinary history, and coordinate with boards of medicine and nursing, attorneys general, law enforcement, the FDA, and the National Association of Boards of Pharmacy.
The article points to Ohio as an example of a state warning licensees that compounding, selling, ordering, administering, or facilitating the distribution of retatrutide may lead to discipline, including immediate licence suspension. It also cites enforcement in Ohio and Indiana. These examples concern U.S. jurisdictions; they do not establish that a particular Canadian pharmacy or clinician has acted improperly.
The broader issue is regulatory coordination. A pharmacy licensed in several states can move products across borders, while online advertising and telehealth can make the seller’s location unclear. Without information-sharing between regulators, enforcement may simply push activity into another jurisdiction rather than protect patients.
What this means in Canada
Canada has a different regulatory structure, but the patient-safety lesson is similar. A Canadian website, clinic, or imported vial is not evidence that a product is authorized or that it contains pharmaceutical-grade retatrutide. Health Canada has not approved retatrutide for sale, and legitimate access remains limited to an authorized clinical trial or an exceptional physician-led request through the Special Access Programme.
Canadians who see retatrutide advertised for human use should not self-inject or rely on a pharmacy label as proof of quality. Suspected illegal products can be reported through Health Canada’s Health Product Complaint and Incident Reporting system. The Pharmacy Times article’s central warning is therefore relevant on both sides of the border: demand for a promising medicine can create incentives for unsafe supply before regulators have confirmed that the medicine is ready for routine care.